TITLE

Ensuring drug safety in health systems: Role of the Food and Drug Administration Amendments Act of 2007, risk evaluation and mitigation strategies, and restricted drug distribution systems

PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS21
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents several learning objectives and assessment questions for readers of the journal upon completion of the articles in the November 15, 2009, issue. The article states that readers should be able to discuss various provisions of the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, describe risk assessment strategies among health-system pharmacists, and and answer questions about the reasons for the passage of the FDAAA of 2007.
ACCESSION #
48713911

 

Related Articles

  • Specialty pharmacies and other restricted drug distribution systems: Financial and safety considerations for patients and health-system pharmacists. Kirschenbaum, Bonnie E. // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS13 

    Purpose. To discuss the role of restricted drug distribution systems in the implementation of risk evaluation and mitigation strategies (REMS), health-system pharmacists’ concerns associated with the use of specialty pharmacies and other restricted drug distribution systems, reimbursement...

  • The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications. Shane, Rita // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS2 

    The article examines the implications upon drug safety and health-system pharmacies as a result of the implementation of the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007. The author asserts that the FDAAA enhanced the authority of the FDA during postmarketing of drugs, which...

  • The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications. Meyer, Brian M. // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS3 

    Purpose. To describe the drug safety provisions of the Food and Drug Administration Amendments Act (FDAAA) of 2007, including risk evaluation and mitigation strategies (REMS), and the implications for health-system pharmacists. Summary. The FDAAA grants FDA new authorities to require...

  • Risk evaluation and mitigation strategies: Impact on patients, health care providers, and health systems. Shane, Rita // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS6 

    Purpose. To describe the impetus for and evolution, components, and potential impact on patients, health care providers, and health systems of risk evaluation and mitigation strategies (REMS) required by the Food and Drug Administration (FDA) for managing known or potential serious drug risks....

  • Opportunities for 2008. Wechsler, Jill // Pharmaceutical Technology;Jan2008, Vol. 32 Issue 1, p30 

    The article reports on the strategies that need to be addressed by the U.S. Food and Drug Administration (FDA) for 2008. These include the filing for Risk Evaluation and Mitigation Strategies (REMS) by drug manufacturers under the FDA Amendments Acts (FDAAA), ensuring the safety of drugs made...

  • REMS -- One Year Later. Baker, Danial D. // Hospital Pharmacy;May2010, Vol. 45 Issue 5, p348 

    The author discusses the Risk Evaluation and Mitigation Strategy (REMS) program he initiated in 2009. He traces the development of the scheme which carried an amendment to the U.S. Food and Drug Administration (FDA) Act in 2007 and gave the legal foundation for the advancement of an...

  • Exam gloves go up in smoke.  // AHA News;07/22/96, Vol. 32 Issue 29, p5 

    Reports on the US Food and Drug Administration's warning to hospitals that improperly stored exam gloves pose a fire hazard.

  • FDA Approves REMS for Most Powerful Opioids. Serebrov, Mari // BioWorld Today;7/10/2012, Vol. 23 Issue 132, p2 

    The article reports on the approval of a classwide risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioid drugs by the U.S. Food and Drug Administration (FDA).

  • FDA's New Initiative . Harrold, Dave // Control Engineering;May2003, Vol. 50 Issue 5, p34 

    Focuses on the initiative of the U.S. Food and Drug Administration to include the use of risk-based assessments for identifying and prioritizing risks in the 21 CFR Part 11 regulation. Purpose of the government body to include the risk assessment clause in the regulation; Emphasis on the need...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics